Sacubitril/valsartan: A practical guide

Cândida Fonseca, Dulce Brito, Jorge Ferreira, Fátima Franco, João Morais, José Silva Cardoso

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

© 2019 Sociedade Portuguesa de Cardiologia Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan modulates the neurohormonal axis by inhibiting both angiotensin receptors and neprilysin, and improves neurohormonal balance more than blocking the RAAS alone. The PARADIGM-HF trial validated this new treatment option for patients with HFrEF. Sacubitril/valsartan was also more effective than enalapril in slowing disease progression by decreasing the risk of worsening heart failure requiring hospitalization or emergency admission and the need for intensified therapy, heart failure devices or cardiac transplantation. More than 70% of patients included in PARADIGM-HF were in NYHA class II, and overall, the results indicate that sacubitril/valsartan should be started in the earliest symptomatic stages of the disease. As PARADIGM-HF has excellent robustness for a cardiovascular trial, sacubitril/valsartan has been included as a new treatment option with a strong level of recommendation in the main international guidelines. This expert task force proposes a practical guide to the use of this new drug that has been endorsed by the Working Group on Heart Failure of the Portuguese Society of Cardiology.
Original languageEnglish
JournalRevista Portuguesa de Cardiologia
DOIs
Publication statusPublished - May 2019

Fingerprint

Heart Failure
Renin-Angiotensin System
Neprilysin
Angiotensin Receptors
Enalapril
Advisory Committees
Heart Transplantation
Cardiology
Treatment Failure
Disease Progression
Hospitalization
Emergencies
Therapeutics
LCZ 696
Guidelines
Equipment and Supplies
Pharmaceutical Preparations

Keywords

  • Heart failure with reduced ejection fraction
  • PARADIGM-HF
  • Practical guidance
  • Sacubitril/valsartan

Cite this

Fonseca, Cândida ; Brito, Dulce ; Ferreira, Jorge ; Franco, Fátima ; Morais, João ; Silva Cardoso, José. / Sacubitril/valsartan: A practical guide. In: Revista Portuguesa de Cardiologia. 2019.
@article{be388473da154581b5d23eedf622997d,
title = "Sacubitril/valsartan: A practical guide",
abstract = "{\circledC} 2019 Sociedade Portuguesa de Cardiologia Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan modulates the neurohormonal axis by inhibiting both angiotensin receptors and neprilysin, and improves neurohormonal balance more than blocking the RAAS alone. The PARADIGM-HF trial validated this new treatment option for patients with HFrEF. Sacubitril/valsartan was also more effective than enalapril in slowing disease progression by decreasing the risk of worsening heart failure requiring hospitalization or emergency admission and the need for intensified therapy, heart failure devices or cardiac transplantation. More than 70{\%} of patients included in PARADIGM-HF were in NYHA class II, and overall, the results indicate that sacubitril/valsartan should be started in the earliest symptomatic stages of the disease. As PARADIGM-HF has excellent robustness for a cardiovascular trial, sacubitril/valsartan has been included as a new treatment option with a strong level of recommendation in the main international guidelines. This expert task force proposes a practical guide to the use of this new drug that has been endorsed by the Working Group on Heart Failure of the Portuguese Society of Cardiology.",
keywords = "Heart failure with reduced ejection fraction, PARADIGM-HF, Practical guidance, Sacubitril/valsartan",
author = "C{\^a}ndida Fonseca and Dulce Brito and Jorge Ferreira and F{\'a}tima Franco and Jo{\~a}o Morais and {Silva Cardoso}, Jos{\'e}",
year = "2019",
month = "5",
doi = "10.1016/j.repc.2018.10.008",
language = "English",
journal = "Revista Portuguesa de Cardiologia",
issn = "0870-2551",
publisher = "Sociedade Portuguesa de Cardiologia",

}

Sacubitril/valsartan: A practical guide. / Fonseca, Cândida; Brito, Dulce; Ferreira, Jorge; Franco, Fátima; Morais, João; Silva Cardoso, José.

In: Revista Portuguesa de Cardiologia, 05.2019.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Sacubitril/valsartan: A practical guide

AU - Fonseca, Cândida

AU - Brito, Dulce

AU - Ferreira, Jorge

AU - Franco, Fátima

AU - Morais, João

AU - Silva Cardoso, José

PY - 2019/5

Y1 - 2019/5

N2 - © 2019 Sociedade Portuguesa de Cardiologia Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan modulates the neurohormonal axis by inhibiting both angiotensin receptors and neprilysin, and improves neurohormonal balance more than blocking the RAAS alone. The PARADIGM-HF trial validated this new treatment option for patients with HFrEF. Sacubitril/valsartan was also more effective than enalapril in slowing disease progression by decreasing the risk of worsening heart failure requiring hospitalization or emergency admission and the need for intensified therapy, heart failure devices or cardiac transplantation. More than 70% of patients included in PARADIGM-HF were in NYHA class II, and overall, the results indicate that sacubitril/valsartan should be started in the earliest symptomatic stages of the disease. As PARADIGM-HF has excellent robustness for a cardiovascular trial, sacubitril/valsartan has been included as a new treatment option with a strong level of recommendation in the main international guidelines. This expert task force proposes a practical guide to the use of this new drug that has been endorsed by the Working Group on Heart Failure of the Portuguese Society of Cardiology.

AB - © 2019 Sociedade Portuguesa de Cardiologia Renin-angiotensin-aldosterone system (RAAS) inhibitors are a cornerstone in the treatment of heart failure with reduced ejection fraction (HFrEF). Sacubitril/valsartan modulates the neurohormonal axis by inhibiting both angiotensin receptors and neprilysin, and improves neurohormonal balance more than blocking the RAAS alone. The PARADIGM-HF trial validated this new treatment option for patients with HFrEF. Sacubitril/valsartan was also more effective than enalapril in slowing disease progression by decreasing the risk of worsening heart failure requiring hospitalization or emergency admission and the need for intensified therapy, heart failure devices or cardiac transplantation. More than 70% of patients included in PARADIGM-HF were in NYHA class II, and overall, the results indicate that sacubitril/valsartan should be started in the earliest symptomatic stages of the disease. As PARADIGM-HF has excellent robustness for a cardiovascular trial, sacubitril/valsartan has been included as a new treatment option with a strong level of recommendation in the main international guidelines. This expert task force proposes a practical guide to the use of this new drug that has been endorsed by the Working Group on Heart Failure of the Portuguese Society of Cardiology.

KW - Heart failure with reduced ejection fraction

KW - PARADIGM-HF

KW - Practical guidance

KW - Sacubitril/valsartan

UR - http://www.scopus.com/inward/record.url?scp=85060142623&partnerID=8YFLogxK

U2 - 10.1016/j.repc.2018.10.008

DO - 10.1016/j.repc.2018.10.008

M3 - Article

JO - Revista Portuguesa de Cardiologia

JF - Revista Portuguesa de Cardiologia

SN - 0870-2551

ER -